Citations

Clear

6 citation(s) found for "Nguyen, Thien".

Hemodynamic Simulation of Brain Arteriovenous Malformation (AVM)
Alsereidi, F, Ueki, Yasuhito , Kadirvel, Ram , Le, Trung B., Nguyen, Thien-Tam, Alsereidi, Fatmah R. , Kadirvel, Ramanathan

Mayo Clinic

2026 Design of Medical Devices Conference | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2026-1028 Get It

Abstract Brain arteriovenous malformations (AVMs) result from abnormal growth of vascular structures. AVMs pose a significant rupture risk, and its treatment is challenging due to the complex hemodynamics within the tangled nidus. Currently, investigating AVM hemodynamics remains a challenge due to the low resolution of clinical imaging modalities. In this study, a high-fidelity Computational Fluid Dynamics (CFD) simulation of a brain AVM from a KRAS-mutated mouse model is developed from micro-CT images. Brain AVMs were induced in mice through systemic delivery of AAV-BR1-CAG vector encoding KRASG12V-GFP transgene to cerebral endothelial cells. High-resolution microCT imaging at 6.551 šœ‡š‘š pixel size captured the complex vascular anatomy. The cerebral arteries were reconstructed using the 3D Slicer and Blender software. The curvilinear immersed boundary (CURVIB) method was employed with approximately 65 million grid points and spatial resolution of 0.7āˆ’2.3 šœ‡š‘š. Our preliminary results reveal heterogeneous flow distribution through the nidus, with blood channeling through two primary pathways. The extremely low Reynolds number (0.038) indicates viscous-dominated flow characteristic of microcirculation. Our work presents the first high-resolution CFD simulation of brain AVM in the literature, providing a foundation for investigating flow-mediated vascular remodeling, rupture risk assessment, and therapeutic intervention planning in future.
In Children, N-Methyl-D-Aspartate Receptor Antibody Encephalitis Incidence Exceeds That of Japanese Encephalitis in Vietnam
Hʰʔng, Nguyį»…n HoĆ ng ThiĆŖn , Toan, Nguyen Duc , Thien, T , Khanh, Truong Huu, Tuan, Nguyen Minh, Nguyen, Nghia An , Thinh, Le Quoc, Thoa, Nguyen Thi Kim, Nhan, Le Nguyen Thanh, Minh, Ngo Ngį»c Quang, Thwaites, Louise , Hùng, Nguyį»…n Thanh , Irani, Sarosh R. , Quy, Dʰ Tuįŗ„n, Thien, Tran Ba , Nghia, Nguyen An , Turner, Hugo C , Thwaites, C Louise , Hung, Nguyen Thanh , Tan, Le Van , Irani, Sarosh R , Tuan, Nguyen Minh, Truc, Tran Thanh

Mayo Clinic

Open Forum Infectious Diseases | November 28, 2024 | Volume: 11 | Issue: 12 | Pages: No page available

10.1093/ofid/ofae710 | PMID 39691294 Get It

Abstract Background The recognition of autoimmune causes of encephalitis has led to epidemiological shifts in the worldwide characteristics of encephalitis. N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis leads to well-established complex neuropsychiatric manifestations. In low- and middle-income countries, including Vietnam, its relative incidence, especially in children, is unknown and most neurologists currently consider infectious encephalitis prior to autoimmune etiologies. Methods The study was prospectively conducted at Children's Hospital 1 in Ho Chi Minh City between March 2020 and December 2022. Any child admitted to the Department of Infectious Diseases and Neurology fulfilling the case definition of encephalitis was eligible to participate. Cerebrospinal fluid samples were collected alongside meta-clinical data for analysis. Results We recruited 164 children with a clinical diagnosis of encephalitis. Etiologies were determined as NMDAR antibody encephalitis in 23 of 164 cases (14.0%), Japanese encephalitis virus in 14 of 164 (8.5%), and herpes simplex virus in 4 of 164 (2.4%). Clinical categorizations suggested idiopathic viral encephalitis in another 71 (43.3%), and autoimmune encephalitis of unknown origin in the remaining 52. Factors including demographics, specific clinical features, cerebrospinal fluid and electroencephalogram findings, and length of hospital stay were significantly different between NMDAR antibody encephalitis and Japanese encephalitis. Conclusions At a tertiary children's hospital in Vietnam, the prevalence of NMDAR antibody encephalitis exceeds that of Japanese encephalitis, the most common infectious encephalitis cause in Southeast Asia. NMDAR antibody encephalitis is associated with long hospital stay and poor outcomes. These findings should change pediatric diagnostics, to earlier consider autoimmune treatments in this clinical setting.
A Cost of Illness Analysis of Children with Encephalitis Presenting to a Major Hospital in Vietnam
Hʰʔng, Nguyį»…n HoĆ ng ThiĆŖn , Toan, Nguyen Duc , Khanh, Truong Huu, Thinh, Le Quoc, Nhan, Le Nguyen Thanh, Minh, Ngo Ngį»c Quang, Thoa, Nguyen Thi Kim, Hùng, Nguyį»…n Thanh , Quy, Dʰ Tuįŗ„n, Thwaites, Louise , Irani, Sarosh R. , Irani, Sarosh R , Thwaites, C Louise , Tan, Le Van , Turner, Hugo C

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | November 19, 2024 | Volume: 112 | Issue: 2 | Pages: 422-430

10.4269/ajtmh.24-0409 | PMID 39561390 Get It

ABSTRACT. Encephalitis is a significant global health problem, especially in children. Knowledge of its economic burden is essential for policymakers in prioritizing the development and implementation of interventions but remains limited. An observational study was prospectively conducted at a major children’s hospital in Ho Chi Minh City, Vietnam from 2020 to 2022. Data on direct medical costs, direct nonmedical costs, and productivity costs were collected alongside demographic information, clinical features, diagnosis, severity, and outcomes of study participants. This was used to undertake a cost of illness analysis from a societal perspective. Data were collected from a total of 164 pediatric patients. The median cost of illness was estimated at US $1,859 (interquartile range [IQR]: US $1,273–$3,128). The direct costs were the main cost driver, accounting for 83.9% of the total cost of illness (US $1,560; IQR: US $975–$2,460). The productivity costs accounted for a median of US $275 (IQR: US $154–$474). The cost of illness was higher in more severe patients, patients with sequelae, patients with morbidities, and ventilated patients. Most direct medical costs were attributed to hospitalization and resulted in out-of-pocket payments from the patient’s family (30.2%; US $316). The results showed that the cost of illness of encephalitis in children is considerable and will be useful for policymakers in prioritizing resources for the development and implementation of intervention strategies to reduce the burden of pediatric encephalitis.
Abstract PO2-12-08: Increased burden of genetic variants in idiopathic cardiomyopathy genes is associated with cancer therapy-related cardiomyopathy
Norton, Nadine , Nguyen, Thien , Reddy, Joseph S. , Harvey, Jinky, Weidner, Morgan, Evans, Lily, Vallow, Laura A., Advani, Pooja , Norton, Nadine , Arnold, Amanda

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-08-PO2-12-08

10.1158/1538-7445.sabcs23-po2-12-08 Get It

Abstract Background: Breast cancer (BC) patients are at significant risk of therapy-related cardiotoxicity, but prediction of which patients will experience cardiotoxicity and the severity of the outcome are lacking. We hypothesized that germline genetic variants are potential risk factors for cancer treatment-related cardiomyopathy (CTRC) and in this study, we focused on rare non-synonymous variants within 57 genes deemed causative of familial and sporadic forms of idiopathic cardiomyopathies. Methods: We developed a clinical database and biorepository for patients receiving any potentially cardiotoxic cancer therapy at Mayo Clinic Florida. Enrollment is ongoing and includes consent to access external records. Patient data is extracted from records at baseline, completion of treatment and then once per year. The clinical database includes the following datasets: demographics, pathology, chemotherapy, radiation, echocardiography, cardiac MRI, PET/CT scan, blood pressure, BMI, labs, treatment complications. Treatment complications includes pre-existing conditions (smoking, alcohol and drug use history, hypertension, diabetes, coronary artery disease, hyperlipidemia, prior stroke or myocardial infarction, peripheral vascular disease, renal failure); cardiac medications at baseline; cardiac side-effects; time to cardiotoxicity; cardiotoxicity interventions and outcomes. Exome sequencing was performed by the Mayo Clinic NGS core on the first 86 patients in the registry, average of ~120x read depth following Illumina’s standard protocol for the NovaSeq 6000 and S4 flow cell. Genomic variants were extracted for 57 genes known to be causative of dilated, hypertrophic and arrhythmogenic right ventricular cardiomyopathies and channelopathies. Putative risk variants in known cardiomyopathy genes were defined as non-synonymous variants with a frequency of < 0.0004 in the GnomAD database. We compared the number of patients with putative risk variants in those groups with and without CTRC. Results: 84/86 patients had BC diagnosis. Key characteristics are described in the table below. 60/86 (70%) patients had at least one putative risk variant in one of 31 genes (there were no risk variants identified in 27/57 genes). The average number of putative risk variants per patient within the CTRC group was higher than that observed in patients without CTRC (2.06 vs 1.62). Post-hoc analysis suggested this difference is largely from patients with >2 risk variants in the group who experienced CTRC (N=7/17, 41%) compared to those who did not (N=14/69, 20%), p=0.023. Conclusions: Rare missense variants in the causative genes of idiopathic cardiomyopathies are potential risk factors for CTRC and risk may be increased in patients with a higher burden of variants. Analysis of the genetic data from patients that continue to be accrued in this study, including effects of additional clinical risk factors will be undertaken to improve prediction of cardiotoxicity. Table 1 Distribution of putative cardiomyopathy genetic variants in 86 cancer patients with and without treatment-related cardiomyopathy, separated by treatment regimen Citation Format: Nadine Norton, Thien Nguyen, Joseph Reddy, Jinky Harvey, Morgan Weidner, Amanda Arnold, Lily Evans, Laura Vallow, Pooja Advani. Increased burden of genetic variants in idiopathic cardiomyopathy genes is associated with cancer therapy-related cardiomyopathy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-08.
Abstract 1956: miR-181d degradation mediated genetic heterogeneity and acquired resistance
Ramakrishnan, Valya, Akers, Johnny, Nguyen, Thien , Wang, Aaron , Adhikari, Bandita, Hirshman, Brian R. , Hua, Wei , Ying, Mao, Nitta, Masayuki, Chen, Clark C. , Li, Jie , Sarkaria, Jann N. , Hua, Wei, Ying, Mao, Jiang, Tao , Carter, Bob S.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 1956-1956

10.1158/1538-7445.am2018-1956 Get It

Abstract When unrepaired, alkylated DNA can induce cell death or trigger mutagenesis. Cellular capacity for repair of these lesions by O6-methylguanine methyltransferase (MGMT) dictates the equilibrium between cell viability and genetic diversity. Treatment of glioblastoma cells with temozolomide (TMZ) induced ATM- and Rad3-related (ATR) kinase dependent polyribonucleotide nucleotidyltransferase 1 (PNPT1) degradation of miR-181d. miR-181d suppresses MGMT expression; its degradation increases the mean MGMT expression of the cell population. miR-181d degradation also magnifies the cell-to-cell variability in MGMT expression, expanding the genetic heterogeneity of the population. This expanded heterogeneity enhances the ā€œfitnessā€ of the population and constitutes a novel form of chemotherapeutic resistance. These effects can be suppressed by overexpression of miR-181d, suggesting miRNA delivery as a strategy for glioblastoma therapy. To characterize the mechanism of acquired resistance, we profiled the expression of 2400 miRNAs before and after TMZ treatment. In independent patient-derived neurosphere lines, the majority of miRNAs remained unchanged after treatment. However, miR-181d was consistently suppressed after TMZ treatment. Our previous work demonstrated miR-181d as the master regulator of MGMT. We confirmed TMZ-induced suppression of miR-181d using independent in vitro and in vivo models as well as matched pre- and post-TMZ treated clinical specimens. TMZ-induced miR-181d suppression persisted after transcriptional inhibition, suggesting degradation as the primary mechanism. We performed an siRNA screen and identified polyribonucleotide nucleotidyltransferase 1 (PNPT1) as the gene responsible for miR-181d degradation. CRISPR inactivation of PNPT1 eliminated TMZ-induced suppression of miR-181d; this was rescued by wild-type PNPT1 but not by PNPT1 harboring RNAse-inactivating mutations. TMZ-induced degradation of miR-181d requires ATR kinase. Silencing or inhibition of ATR eliminated binding of PNPT1 to miR-181d and prevented degradation of miR-181d. TMZ-sensitizing effects of ATR inhibition were reversed by anti-miR-181d, suggesting miR-181d is essential in this process. In addition to elevating the mean MGMT expression of the population, single-cell analysis revealed that miR-181d degradation broadened the cell-to-cell variability in MGMT expression in vitro. In matched clinical pre- and post-TMZ treated specimens, variability in MGMT expression was significantly elevated in post-TMZ samples. This was recapitulated using The Cancer Genome Atlas (TCGA) database. We propose that miR-181d degradation-mediated expansion of genetic heterogeneity enhances the ā€œfitnessā€ of the population, constituting a novel form of chemotherapeutic resistance. These effects are suppressed by miR-181d overexpression, suggesting miRNA delivery as a strategy for glioblastoma therapy. Citation Format: Valya Ramakrishnan, Johnny Akers, Thien Nguyen, Aaron Wang, Bandita Adhikari, Brian Hirshman, Jie Li, Jann Sarkaria, Wei Hua, Mao Ying, Masayuki Nitta, Tao Jiang, Bob Carter, Clark C. Chen. miR-181d degradation mediated genetic heterogeneity and acquired resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1956.
A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas
Kushwaha, Deepa, Ramakrishnan, Valya, Ng, Kimberly, Nguyen, Thien , Futalan, Diahnn, Akers, Johnny, Jiang, Tao , Chen, Clark C. , Sarkaria, Jann, Steed, Tyler , Sarkaria, Jann N. , Chowdhury, Dipanjan , Carter, Bob S.

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 5 | Issue: 12 | Pages: 4026-4039

10.18632/oncotarget.1974 | PMID 24994119 Get It